NeuroSense Therapeutics (NASDAQ:NRSN) Trading Up 3.3%

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN)’s share price shot up 3.3% on Friday . The company traded as high as $0.55 and last traded at $0.53. 388,555 shares traded hands during mid-day trading, a decline of 22% from the average session volume of 498,123 shares. The stock had previously closed at $0.51.

NeuroSense Therapeutics Stock Performance

The company has a quick ratio of 2.80, a current ratio of 2.52 and a debt-to-equity ratio of 0.04. The firm has a market cap of $5.81 million, a price-to-earnings ratio of -0.41 and a beta of -0.63. The business’s 50-day simple moving average is $0.61 and its two-hundred day simple moving average is $1.12.

NeuroSense Therapeutics (NASDAQ:NRSN) last released its quarterly earnings results on Wednesday, August 16th. The company reported ($0.44) earnings per share for the quarter.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Point72 Asset Management L.P. purchased a new stake in NeuroSense Therapeutics in the 2nd quarter worth $149,000. Meitav Investment House Ltd. acquired a new position in shares of NeuroSense Therapeutics during the 1st quarter worth about $193,000. Jane Street Group LLC raised its position in shares of NeuroSense Therapeutics by 77.6% during the 2nd quarter. Jane Street Group LLC now owns 77,249 shares of the company’s stock worth $261,000 after purchasing an additional 33,751 shares during the last quarter. Renaissance Technologies LLC purchased a new position in NeuroSense Therapeutics in the 3rd quarter valued at about $97,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in NeuroSense Therapeutics in the 2nd quarter worth about $134,000. 0.67% of the stock is owned by institutional investors and hedge funds.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis.